PTC Therapeutics International Limited – Duchenne muscular dystrophy

Access Program Information

<p>This study is being performed as a <strong>post-approval safety study (PASS)</strong>, per the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA), to gather data on <strong>Translarna (<span class=”hit_inf”>ataluren; PTC124</span>)</strong> safety, effectiveness, and prescription patterns in routine clinical practice for patients with <em>Duchenne&nbsp;Muscular&nbsp;Dystrophy</em>.</p>
<p>Expanded access is no longer available for this treatment. For further information please call PTC Pharmaceuticals.</p>